Ilikai Hotel

Ilikai Therapeutics is a biotechnology company focused on developing next-generation treatments for chronic pain and neurodegenerative diseases. Spun out from the University of Oxford, the company leverages a proprietary platform that combines human genetics with advanced functional genomics to identify and validate novel drug targets. Their primary focus is on addressing the significant unmet need in pain management by developing precision medicines that target specific ion channels and pathways identified through patient genetic data. The company's pipeline currently features several pre-clinical programs aimed at neuropathic pain and conditions like Amyotrophic Lateral Sclerosis (ALS).